On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.

On the news front, the company announced that its core product, the Toumai laparoscopic surgical robot, has achieved over 200 global commercial installations, all with end-customer acceptance reports secured. Global commercial orders have surpassed 300 units with total orders approaching 400, and first-half new orders have already exceeded the full-year total for last year. The latest installation was completed at Spain's HM Hospitales, with year-to-date global new installations ranking first among domestic peers and second globally.

Additionally, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. UBS, JP Morgan, and CITIC Construction Investment have all issued positive ratings, citing strong overseas sales potential and a path toward breakeven in the first half of this year. UBS raised its target price to HKD 35.9 with a Buy rating, projecting a revenue CAGR of 49.5% through 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)